{
  "id": 18395,
  "title": "Lenacapavir will slow HIV infections if there's enough of it and it reaches at-risk groups",
  "url": "https://urgent.news/2026/07/25/lenacapavir-will-slow-hiv-infections-if-theres-enough-of-it-and-it",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-07-25T17:04:00.000Z",
  "source": {
    "name": "Deutsche Welle Science",
    "slug": "deutsche-welle-science",
    "url": "https://www.dw.com/en/lenacapavir-will-slow-hiv-infections-if-there-s-enough-of-it-and-it-reaches-at-risk-groups/a-78075943?maca=en-rss-en-science-4552-rdf"
  },
  "original_language": "en",
  "account": "Lenacapavir, a new HIV pre-exposure prophylaxis (PrEP) drug, offers a potential solution to the high adherence challenges faced by individuals at risk of HIV infection. Unlike traditional PrEP pills that require daily doses, Lenacapavir is administered via a single injection every six months, making adherence far easier to maintain. This convenience is particularly beneficial for those who may otherwise struggle to consistently take daily medication due to forgetfulness, resistance, stigma, or side effects.\n\nHowever, Lenacapavir's effectiveness hinges on proper distribution and access, especially among those most at risk. Studies suggest that if at least 2-4% of the adult population in high-risk areas receives the injection, it could potentially avert 12-18% of new HIV infections over a decade. This significant impact depends heavily on making the drug affordable and accessible to those who need it most.\n\nDespite these promising findings, challenges remain. The drug's high cost and limited distribution in some regions, including Latin American countries like Brazil, Mexico, Peru, and Argentina, hinder its widespread adoption. Moreover, even within eligible countries, vulnerable populations may still be overlooked. Access to Lenacapavir remains a critical factor in the fight against HIV, but simply providing the drug is not enough. Identifying and reaching out to those most at risk is equally, if not more, important to make a meaningful dent in the epidemic.",
  "summary": "Lenacapavir is one injection, twice a year. It's a big improvement for people in high-risk groups, currently taking a pill a day against HIV infection. But its long-term impact depends on it reaching those very people.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}